Literature DB >> 26092831

Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods.

Elamin H Elbasha1, Jagpreet Chhatwal2.   

Abstract

BACKGROUND: Modeling guidelines recommend applying a half-cycle correction (HCC) to outcomes from discrete-time state-transition models (DTSTMs). However, there is still no consensus on why and how to perform the correction. The objective was to provide theoretical foundations for HCC and to compare (both mathematically and numerically) the performance of different correction methods in reducing errors in outcomes from DTSTMs.
METHODS: We defined 7 methods from the field of numerical integration: Riemann sum of rectangles (left, midpoint, right), trapezoids, life-table, and Simpson's 1/3rd and 3/8th rules. We applied these methods to a standard 3-state disease progression Markov chain to evaluate the cost-effectiveness of a hypothetical intervention. We solved the discrete- and continuous-time (our gold standard) versions of the model analytically and derived expressions for various outcomes including discounted quality-adjusted life-years, discounted costs, and incremental cost-effectiveness ratios.
RESULTS: The standard HCC method gave the same results as the trapezoidal rule and life-table method. We found situations where applying the standard HCC can do more harm than good. Compared with the gold standard, all correction methods resulted in approximation errors. Contrary to conventional wisdom, the errors need not cancel each other out or become insignificant when incremental outcomes are calculated. We found that a wrong decision can be made with a less accurate method. The performance of each correction method vastly improved when a shorter cycle length was selected; Simpson's 1/3rd rule was the fastest method to converge to the gold standard.
CONCLUSION: Cumulative outcomes in DTSTMs are prone to errors that can be reduced with more accurate methods like Simpson's rules. We clarified several misconceptions and provided recommendations and algorithms for practical implementation of these methods.
© The Author(s) 2015.

Keywords:  continuous time; discrete time; half-cycle correction; numerical integration; state-transition models

Mesh:

Year:  2015        PMID: 26092831     DOI: 10.1177/0272989X15585121

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  11 in total

1.  Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers.

Authors:  Elamin H Elbasha; Jagpreet Chhatwal
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

Review 2.  Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.

Authors:  Jagpreet Chhatwal; Tianhua He; Maria A Lopez-Olivo
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

3.  Changing Cycle Lengths in State-Transition Models: Challenges and Solutions.

Authors:  Jagpreet Chhatwal; Suren Jayasuriya; Elamin H Elbasha
Journal:  Med Decis Making       Date:  2016-07-01       Impact factor: 2.583

4.  Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System.

Authors:  Yongrui Bai; Yuejuan Xu; Bin Wu
Journal:  Gastroenterol Res Pract       Date:  2017-11-26       Impact factor: 2.260

5.  A theoretical foundation for state-transition cohort models in health decision analysis.

Authors:  Rowan Iskandar
Journal:  PLoS One       Date:  2018-12-11       Impact factor: 3.240

6.  Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.

Authors:  Jiangping Yang; Jiaqi Han; Maolang Tian; Kun Tian; Wenjun Liao; Xi Yan
Journal:  Cancer Manag Res       Date:  2020-12-15       Impact factor: 3.989

7.  Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention.

Authors:  Torbjørn Wisløff; Dan Atar
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2016-01-01

8.  Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.

Authors:  Bin Wu; Qiang Zhang; Jie Sun
Journal:  J Immunother Cancer       Date:  2018-11-20       Impact factor: 13.751

9.  Greater Glycemic Burden Is Associated with Further Poorer Glycemic Control in Newly-Diagnosed Type 2 Diabetes Mellitus Patients.

Authors:  Wei-Lun Wen; Hui-Chun Huang; Hsiu-Chu Lin; Wan-Ching Lo; Szu-Chia Chen; Mei-Yueh Lee
Journal:  Nutrients       Date:  2022-01-13       Impact factor: 5.717

10.  The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.

Authors:  E H Elbasha; M N Robertson; C Nwankwo
Journal:  Aliment Pharmacol Ther       Date:  2016-12-01       Impact factor: 9.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.